Save on Myrbetriq with Coupons, Discounts & Savings Programs

Myrbetriq is the brand name for mirabegron and is available as an extended-release oral tablet and suspension.

Myrbetriq is available in the following:

• Extended-release tablets: 25 mg and 50 mg.
• For extended-release oral suspension: 8 mg/mL of mirabegron after reconstitution

Myrbetriq is a beta-3 agonist that is used to treat:

• Overactive bladder in adults
• Neurogenic detrusor overactivity (NDO) in children ages 3 years and older

Myrbetriq is a beta agonist that activates (wakes up) certain proteins in your bladder that cause your bladder muscles to relax. This makes the bladder to hold on to more urine, allowing you to go to the bathroom less often.

Myrbetriq is dosed as follows:

Overactive bladder (OAB)

• Adults (Myrbetriq tablets): The typical starting dose is 25 mg by mouth once a day. It can be taken alone or together with 5 mg of solifenacin (Vesicare). If needed, your healthcare provider might raise your dose to 50 mg once a day after 1 to 2 months

Neurogenic detrusor overactivity (NDO)

Children 77 pounds (35 kg) or less:

• Myrbetriq granules: Your child’s provider will determine the dose based on your child’s body weight. The dose typically ranges from 24 mg to 64 mg by mouth once daily.

Children 77 pounds (35 kg) or more:

• Myrbetriq tablets: The typical starting dose is 25 mg by mouth once a day. If needed, your healthcare provider might raise your dose to 50 mg once a day after 1 to 2 months
• Myrbetriq granules: The typical starting dose is 48 mg by mouth once a day. If needed, your child’s provider might raise the dose to 80 mg once a day after 1 to 2 months

Your dose might differ if you have kidney or liver problems.

Myrbetriq is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Myrbetriq:

• Overactive bladder
• High blood pressure
• Common cold symptoms
• Urinary tract infection
• Headache
• Constipation
• Upper respiratory tract infection

Neurogenic detrusor overactivity

• Urinary tract infection
• Common cold symptoms
• Constipation
• Headache
• Nausea

Serious side effects are rare with Myrbetriq. Contact your healthcare provider immediately if you experience any of the following.

• Angioedema: swelling of your face, lips, tongue and/or throat
  High blood pressure: headache, vision changes, dizziness

The following medications may interact with Myrbetriq:

• Drugs Metabolized by CYP2D6: Mirabegron is a CYP2D6 inhibitor and, when used concomitantly with drugs metabolized by CYP2D6
• especially narrow therapeutic index drugs, appropriate monitoring and possible dose adjustment of those drugs may be necessary
• Digoxin: When initiating a combination of mirabegron and digoxin with or without solifenacin succinate, use the lowest dose of digoxin; monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect

Astellas Pharma

It is not known if Myrbetriq tablets or Myrbetriq GRANULES will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.

• Mirabegron Extended-Release